Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer

Trial Profile

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Palbociclib (Primary) ; Goserelin; Letrozole; Tamoxifen
  • Indications Adenocarcinoma; Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms NeoRHEA
  • Most Recent Events

    • 26 Nov 2018 Planned End Date changed from 1 Jan 2020 to 1 Mar 2020.
    • 26 Nov 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.
    • 25 Sep 2018 Planned End Date changed from 1 Jul 2020 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top